Biologic Therapy in Adult-Onset Still’s Disease: Treatment Patterns and Clinical Outcomes from a Real-World Cohort
Rheumatology Quartely , ss.152-160, 2026 (Hakemli Dergi)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.65717/qrheumatol.2026.26067
- Dergi Adı: Rheumatology Quartely
- Sayfa Sayıları: ss.152-160
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Abstract
Objective: To investigate the clinical characteristics, biologic treatment patterns, and long-term outcomes of patients with adult-onset Still’s disease (AOSD) requiring biologic therapy in a real-world setting.
Methods: This single-center retrospective study reviewed patients fulfilling the Yamaguchi classification criteria for AOSD between January 2010 and December 2021. Clinical characteristics, biologic treatment patterns, treatment outcomes, and safety were assessed in patients who received biologic therapy. Data were summarized using descriptive statistics.
Results: Among 49 patients diagnosed with AOSD, 9 (18.4%) received biologic therapy during follow-up (median age at diagnosis, 26 years; 77.8% female). Biologic therapy was initiated a median of 37 months after diagnosis. Indications for biologic therapy were persistent systemic inflammation (55.6%) and refractory arthritis (44.4%). Tocilizumab was the most frequently used initial biologic (33.3%), followed by tumor necrosis factor inhibitors (etanercept 22.2% and infliximab 22.2%) and anakinra (22.2%). Over a median follow-up of 121 months, the median duration of biologic therapy was 95 months. Five patients (55.6%) required biologic switching because of inadequate response or adverse events; both patients treated with infliximab discontinued therapy because of severe infusion reactions. Following biologic initiation, glucocorticoids were tapered to ≤5 mg/day prednisolone equivalent in all patients, with complete withdrawal achieved in 2 (22.2%). Sustained remission after biologic discontinuation was achieved in 2 patients. No serious infections, malignancies, or deaths occurred during follow-up.
Conclusion: In this long-term real-world cohort of refractory AOSD, biologic therapy enabled substantial glucocorticoid reduction and prolonged treatment persistence. Sustained remission after biologic discontinuation was achieved in a subset of patients.